The U.S. anesthesia industry is facing several headwinds in 2024. From the impact of declining CMS reimbursements to ongoing staffing shortages and the interference of weight loss medications, including glucagon-like peptide 1 receptors, on patients, leaders have a lot to grapple with.
Why this U.S. Anesthesia Partners exec is excited about AI in the operating room
